Verrica Pharma

$8.10 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Verrica Pharma

Verrica Pharmaceuticals Inc. is a United States-based clinical-stage medical dermatology company. The Company is focused on identifying, developing and commercializing pharmaceutical products for the treatment of skin diseases with unmet needs. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin. The Company also intends to develop second cantharidin-based product candidate, VP-103, for the treatment of plantar warts. The Company has completed one Phase II clinical trial of topical solution of cantharidin administered with the wooden stick part of a cotton-tipped swab. It also conducting another Phase II clinical trial of topical solution of cantharidin administered through applicator, which collectively refer to as VP-102, for the treatment of molluscum.

Stock Analysis

last close $8.01
1-mo return -12%
3-mo return -35.4%
avg daily vol. 51.21T
52-week high 18.42
52-week low 7.83
market cap. $229M
forward pe -
annual div. -
roe -95.7%
ltg forecast -
dividend yield -
annual rev. $12M
inst own. 33.6%
baraka

Subscribe now for daily local and international financial news

Subscribe